Targeted Genetics collaborates on preventive HIV vaccine trial in Zambia

By Elaine Rigoli

Tampa, Fla., April 26 - Targeted Genetics Corp., the Zambia Emory HIV research project and the International AIDS vaccine initiative have started a clinical trial in Zambia to test the safety and immunogenicity of tgAAC09, a preventive HIV vaccine.

This is the first preventive HIV vaccine trial to be conducted in Zambia,and will take place at the Zambia Emory HIV Research Project Center in Lusaka, according to a news release.

The early stage, multi-national trial is also being conducted at three sites in South Africa and Uganda.

The vaccine candidate, tgAAC09, was developed by Targeted Genetics, the release said.

The vaccine is based on HIV subtype C, the subtype of the virus most prevalent in southern Africa, and tgAAC09 is designed as a preventive vaccine, intended to protect people not infected with HIV from contracting the disease.

It is designed to elicit two different types of immune responses - an antibody response and a cell-mediated response, the release said.

Seattle-based Targeted Genetics is a biotechnology company committed to the development and commercialization of targeted molecular therapies for the prevention and treatment of inflammatory arthritis, HIV/AIDS and other diseases with significant unmet medical need.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.